ppanPersonalized Psychiatry and NeurologyPersonalized Psychiatry and Neurology2712-9179V. M. Bekhterev National Medical Research Centre for Psychiatry and Neurology of the Ministry of Health of the Russian Federation (Bekhterev NMRC PN)10.52667/2712-9179-2023-3-1-42-47ppan-67Research ArticleARTICLEStudy of Associations of the GRM8 Gene with Antipsychoticinduced HyperprolactinemiaPoltavskayaE. G.

Evgeniya G. Poltavskaya

Tomsk

TiguntsevV. V.

Vladimir V. Tiguntsev

Tomsk

BoikoA. S.

Anastasiia S. Boiko

Tomsk

KornetovaE. G.

Elena G. Kornetova

Tomsk

IvanovaS. A.

Svetlana A. Ivanova

Tomsk

FedorenkoO. Yu.

Olga Yu. Fedorenko

Tomsk

f_o_y@mail.ruMental Health Research Institute, Tomsk National Research Medical Center of the Russian Academy of SciencesRussian Federation202317052023314247Copyright © Poltavskaya E.G., Tiguntsev V.V., Boiko A.S., Kornetova E.G., Ivanova S.A., Fedorenko O.Y., 20232023Poltavskaya E.G., Tiguntsev V.V., Boiko A.S., Kornetova E.G., Ivanova S.A., Fedorenko O.Y.Poltavskaya E.G., Tiguntsev V.V., Boiko A.S., Kornetova E.G., Ivanova S.A., Fedorenko O.Y.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.jppn.ru/jour/article/view/67

Hyperprolactinemia is one of the common adverse events of antipsychotic therapy. The role of genetic factors in the development of drug-induced side effects is being actively investigated. The present study examined the association of two polymorphisms rs2237748 and rs2299472 in the GRM8 gene encoding the glutamate metabotropic receptor type 8 with antipsychotic-induced hyperprolactinemia in 536 patients with schizophrenia from several regions of Siberia (Russia). The investigated polymorphisms are not associated with drug-induced hyperprolactinemia in patients with schizophrenia. There were no associations of the GRM8 gene polymorphisms with serum prolactin levels in patients taking antipsychotic therapy. Our results did not confirm the involvement of the GRM8 rs2237748 and rs2299472 in the development of antipsychotic-induced hyperprolactinemia.

hyperprolactinemiaantipsychotic-inducedschizophreniagene polymorphismGRM8ReferencesLaita, P., Cifuentes, A. et al. Antipsychotic relatedabnormal involuntary movements and metabolic and endocrine side effects in children and adolescents. J Child Adolesc Psychopharmacol 2007; 17: 487–502. doi: 10.1089/cap.2006.0039Laita, P., Cifuentes, A. et al. Antipsychotic relatedabnormal involuntary movements and metabolic and endocrine side effects in children and adolescents. J Child Adolesc Psychopharmacol 2007; 17: 487–502. doi: 10.1089/cap.2006.0039Bushe, C., Shaw, M., Peveler, R. A review of the association between antipsychotic use and hyperprolactinaemia. J Psychopharmacol 2008; 22: 46–55. doi: 10.1177/0269881107088435.Bushe, C., Shaw, M., Peveler, R. A review of the association between antipsychotic use and hyperprolactinaemia. J Psychopharmacol 2008; 22: 46–55. doi: 10.1177/0269881107088435.Cookson, J., Hodgson, R., Wildgust, H.J. Prolactin, hyperprolactinaemia and antipsychotic treatment: a review and lessons for treatment of early psychosis. J Psychopharmacol 2012; 26: 42–51. doi: 10.1177/0269881112442016Cookson, J., Hodgson, R., Wildgust, H.J. Prolactin, hyperprolactinaemia and antipsychotic treatment: a review and lessons for treatment of early psychosis. J Psychopharmacol 2012; 26: 42–51. doi: 10.1177/0269881112442016Beasley, C.M. Jr., Magnusson, M., Garver, D.L. TSH response to TRH and haloperidol response latency in psychoses. Biol. Psychiatry 1988, 24(4): 423-431. doi: 10.1016/0006-3223(88)90179-5.Beasley, C.M. Jr., Magnusson, M., Garver, D.L. TSH response to TRH and haloperidol response latency in psychoses. Biol. Psychiatry 1988, 24(4): 423-431. doi: 10.1016/0006-3223(88)90179-5.Farde, L., Nordstrem, A.L. et al. Positron emission tomographic analysis of central Dl and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: relation to extrapyramidal side-effects. Arch. Gen. Psychiatry 1992; 49: 538–544. doi: 10.1001/archpsyc.1992.01820070032005.Farde, L., Nordstrem, A.L. et al. Positron emission tomographic analysis of central Dl and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: relation to extrapyramidal side-effects. Arch. Gen. Psychiatry 1992; 49: 538–544. doi: 10.1001/archpsyc.1992.01820070032005.Kufferle, B., Tauscher, J., Asenbaum, S. IBZM SPECT imaging of striatal dopamin-2 receptors in psychotic patients treated with the novel antipsychotic substance quetiapine in comparison to clozapine and haloperidol. Psychopharmacology 1997; 133: 323-328. doi: 10.1007/s002130050409.Kufferle, B., Tauscher, J., Asenbaum, S. IBZM SPECT imaging of striatal dopamin-2 receptors in psychotic patients treated with the novel antipsychotic substance quetiapine in comparison to clozapine and haloperidol. Psychopharmacology 1997; 133: 323-328. doi: 10.1007/s002130050409.Kapur, S., Remington, G. Dopamine (D2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient. Biol. Psychiatry 2001; 50(11): 873-883. doi: 10.1016/s0006-3223(01)01251-3.Kapur, S., Remington, G. Dopamine (D2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient. Biol. Psychiatry 2001; 50(11): 873-883. doi: 10.1016/s0006-3223(01)01251-3.Perkins, D.О. Prolactin- and Endocrine-Related Disorders in Schizophrenia / Medical Illnes and Schizofrenia, ed. by Meyer J.M. and Nasrallah H.A.; Amer. Psychiatr. Publ. Washington, London, 2003; 215-232.Perkins, D.О. Prolactin- and Endocrine-Related Disorders in Schizophrenia / Medical Illnes and Schizofrenia, ed. by Meyer J.M. and Nasrallah H.A.; Amer. Psychiatr. Publ. Washington, London, 2003; 215-232.Login, I.S. Direct stimulation of pituitary prolactin release by glutamate. Life Sci. 1990, 47(24): 2269-2275. doi: 10.1016/0024- 3205(90)90158-n.Login, I.S. Direct stimulation of pituitary prolactin release by glutamate. Life Sci. 1990, 47(24): 2269-2275. doi: 10.1016/0024- 3205(90)90158-n.Ohi, K., Hashimoto, R. et al. Glutamate networks implicate cognitive impairments in schizophrenia: genome-wide association studies of 52 cognitive phenotypes Schizophr Bull 2014; 41(4): 909-918. doi: 10.1093/schbul/sbu171.Ohi, K., Hashimoto, R. et al. Glutamate networks implicate cognitive impairments in schizophrenia: genome-wide association studies of 52 cognitive phenotypes Schizophr Bull 2014; 41(4): 909-918. doi: 10.1093/schbul/sbu171.Sanacora, G., Zarate, C.A. et al. Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders Nat Rev Drug Discov 2008, 7: 426–437. doi: 10.1038/nrd2462.Sanacora, G., Zarate, C.A. et al. Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders Nat Rev Drug Discov 2008, 7: 426–437. doi: 10.1038/nrd2462.Pin, J.P., Duvoisin, R. The metabotropic glutamate receptors: Structure and functions. Neuropharmacology 1995; 34: 1–26. doi: 10.1016/0028-3908(94)00129-g.Pin, J.P., Duvoisin, R. The metabotropic glutamate receptors: Structure and functions. Neuropharmacology 1995; 34: 1–26. doi: 10.1016/0028-3908(94)00129-g.Plitman, E., Nakajima, S. et al. Glutamatemediated excitotoxicity in schizophrenia: a review. Eur Neuropsychopharmacol: J Eur Coll Neuropsychopharmacol 2014; 24(10): 591-1605. doi: 10.1016/j.euroneuro.2014.07.015.Plitman, E., Nakajima, S. et al. Glutamatemediated excitotoxicity in schizophrenia: a review. Eur Neuropsychopharmacol: J Eur Coll Neuropsychopharmacol 2014; 24(10): 591-1605. doi: 10.1016/j.euroneuro.2014.07.015.Scherer, S.W., Duvoisin, R.M. et al. Localization of two metabotropic glutamate receptor genes,GRM3andGRM8, to human chromosome 7q. Genomics 1996; 31: 230–233. doi: 10.1006/geno.1996.0036.Scherer, S.W., Duvoisin, R.M. et al. Localization of two metabotropic glutamate receptor genes,GRM3andGRM8, to human chromosome 7q. Genomics 1996; 31: 230–233. doi: 10.1006/geno.1996.0036.Zhang, L., Zhong, X. et al. Association analysis of the GRM8 gene with schizophrenia in the Uygur Chinese population. Hereditas 2014; 151(6): 140-144. doi: 10.1111/hrd2.00045.Zhang, L., Zhong, X. et al. Association analysis of the GRM8 gene with schizophrenia in the Uygur Chinese population. Hereditas 2014; 151(6): 140-144. doi: 10.1111/hrd2.00045.Takaki, H., Kikuta, R. et al. Positive associations of polymorphisms in the metabotropic glutamate receptor type 8 gene (GRM8) with schizophrenia. Am J Med Genet B Neuropsychiatr Genet 2004; 128B(1): 6-14. doi: 10.1002/ajmg.b.20108.Takaki, H., Kikuta, R. et al. Positive associations of polymorphisms in the metabotropic glutamate receptor type 8 gene (GRM8) with schizophrenia. Am J Med Genet B Neuropsychiatr Genet 2004; 128B(1): 6-14. doi: 10.1002/ajmg.b.20108.Tavakkoly-Bazzaz, J., Azarnezhad, A. et al. TCF4 and GRM8 gene polymorphisms and risk of schizophrenia in an Iranian population: a case-control study. Mol Biol Rep 2018; 45(6): 2403-2409. doi: 10.1007/s11033-018-4406-2.Tavakkoly-Bazzaz, J., Azarnezhad, A. et al. TCF4 and GRM8 gene polymorphisms and risk of schizophrenia in an Iranian population: a case-control study. Mol Biol Rep 2018; 45(6): 2403-2409. doi: 10.1007/s11033-018-4406-2.World Health Organization. International Statistical Classification of Diseases and Health Related Problems ICD-10; World Health Organization: Geneva, Switzerland, 2004.World Health Organization. International Statistical Classification of Diseases and Health Related Problems ICD-10; World Health Organization: Geneva, Switzerland, 2004.Peuskens, J., Pani, L. et al. The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review. CNS Drugs 2014; 28(5): 421-453. doi: 10.1007/s40263-014-0157-3.Peuskens, J., Pani, L. et al. The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review. CNS Drugs 2014; 28(5): 421-453. doi: 10.1007/s40263-014-0157-3.De Hert, M., Detraux, J., Peuskens, J. Second-generation and newly approved antipsychotics, serum prolactin levels and sexual dysfunctions: a critical literature review. Expert Opinion on Drug Safety 2014; 13(5): 605–624. doi: 10.1517/14740338.2014.906579.De Hert, M., Detraux, J., Peuskens, J. Second-generation and newly approved antipsychotics, serum prolactin levels and sexual dysfunctions: a critical literature review. Expert Opinion on Drug Safety 2014; 13(5): 605–624. doi: 10.1517/14740338.2014.906579.Tandon, R., Belmaker, R.H. et al. World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia; Section of Pharmacopsychiatry, World Psychiatric Association. Schizophrenia Research 2008; 100(1–3): 20–38. doi:10.1016/j.schres.2007.11.033.Tandon, R., Belmaker, R.H. et al. World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia; Section of Pharmacopsychiatry, World Psychiatric Association. Schizophrenia Research 2008; 100(1–3): 20–38. doi:10.1016/j.schres.2007.11.033.Reynolds, G.P., McGowan, O.O., Dalton, C.F. Pharmacogenomics in psychiatry: the relevance of receptor and transporter polymorphisms. British Journal of Clinical Pharmacology 2014; 77(4): 654–672. doi:10.1111/bcp.12312.Reynolds, G.P., McGowan, O.O., Dalton, C.F. Pharmacogenomics in psychiatry: the relevance of receptor and transporter polymorphisms. British Journal of Clinical Pharmacology 2014; 77(4): 654–672. doi:10.1111/bcp.12312.Ivanova, S.A., Osmanova, D.Z. et al. Prolac in gene polymorphism (-1149 G/T) is associated with hyperprolactinemia in patients with schizophrenia treated with antipsychotics. Schizophrenia Research 2017; 182: 110–114. doi: 10.1016/j.schres.2016.10.029.Ivanova, S.A., Osmanova, D.Z. et al. Prolac in gene polymorphism (-1149 G/T) is associated with hyperprolactinemia in patients with schizophrenia treated with antipsychotics. Schizophrenia Research 2017; 182: 110–114. doi: 10.1016/j.schres.2016.10.029.Ivanova, S.A., Osmanova, D.Z. et al. Identification of 5- hydroxytryptamine receptor gene polymorphisms modulating hyperprolactinaemia in antipsychotic drug-treated patients with schizophrenia. The World Journal of Biological Psychiatry 2017; 18(3): 239–246. doi: 10.1080/15622975.2016.1224926.Ivanova, S.A., Osmanova, D.Z. et al. Identification of 5- hydroxytryptamine receptor gene polymorphisms modulating hyperprolactinaemia in antipsychotic drug-treated patients with schizophrenia. The World Journal of Biological Psychiatry 2017; 18(3): 239–246. doi: 10.1080/15622975.2016.1224926.Alladi, C.G., Mohan, A. et al. Risperidone-Induced Adverse Drug Reactions and Role of DRD2 (-141 C Ins/Del) and 5HTR2C (-759 C/T) Genetic Polymorphisms in Patients with Schizophrenia. J Pharmacol Pharmacother 2017; 8(1): 28–32. doi: 10.4103/jpp.JPP_197_16.Alladi, C.G., Mohan, A. et al. Risperidone-Induced Adverse Drug Reactions and Role of DRD2 (-141 C Ins/Del) and 5HTR2C (-759 C/T) Genetic Polymorphisms in Patients with Schizophrenia. J Pharmacol Pharmacother 2017; 8(1): 28–32. doi: 10.4103/jpp.JPP_197_16.Fedorenko, O.Y., Loonen, A.J. et al. Hyperprolactinemia and EYP2D8, DTD2, JVT2E genes polymorphism in patients with schizophrenia. Physiology & Pharmacology 2017; 21(1): 25–33.Fedorenko, O.Y., Loonen, A.J. et al. Hyperprolactinemia and EYP2D8, DTD2, JVT2E genes polymorphism in patients with schizophrenia. Physiology & Pharmacology 2017; 21(1): 25–33.Vadasz, C., Saito, M. et al. Glutamate receptor metabotropic 7 is cis-regulated in the mouse brain and modulates alcohol drinking. Genomics 2007; 90: 690–702. doi: 10.1016/j.ygeno.2007.08.006.Vadasz, C., Saito, M. et al. Glutamate receptor metabotropic 7 is cis-regulated in the mouse brain and modulates alcohol drinking. Genomics 2007; 90: 690–702. doi: 10.1016/j.ygeno.2007.08.006.Fabbri, C., Drago, A., Serretti, A. Early antidepressant efficacy modulation by glutamatergic gene variants in the STAR*D. Eur Neuropsychopharmacol: J Eur Coll Neuropsychopharmacol 2013; 23: 612–621. doi: 10.1016/j.euroneuro.2012.07.006.Fabbri, C., Drago, A., Serretti, A. Early antidepressant efficacy modulation by glutamatergic gene variants in the STAR*D. Eur Neuropsychopharmacol: J Eur Coll Neuropsychopharmacol 2013; 23: 612–621. doi: 10.1016/j.euroneuro.2012.07.006.Fonseca, F., Gratacos, M. et al. Response to methadone maintenance treatment is associated with the MYOCD and GRM6 genes. Mol Diagn Ther 2010; 14: 171–178. doi: 10.1007/BF03256370.Fonseca, F., Gratacos, M. et al. Response to methadone maintenance treatment is associated with the MYOCD and GRM6 genes. Mol Diagn Ther 2010; 14: 171–178. doi: 10.1007/BF03256370.

The authors declare that there are no conflicts of interest present.